2,404 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Guardian Wealth Advisors LLC NC

Guardian Wealth Advisors LLC NC acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,404 shares of the company’s stock, valued at approximately $207,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NVO. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its stake in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. Transce3nd LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at $33,000. Kelly Lawrence W & Associates Inc. CA bought a new position in Novo Nordisk A/S during the 4th quarter valued at $39,000. Finally, Albion Financial Group UT boosted its stake in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

NVO opened at $65.75 on Monday. The stock has a fifty day moving average of $69.21 and a 200-day moving average of $85.83. The firm has a market capitalization of $295.06 billion, a P/E ratio of 19.98, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.